The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease.

The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease. J Clin Gastroenterol. 2017 Jun 21;: Authors: Sokollik C, Fournier N, Rizzuti D, Braegger CP, Nydegger A, Schibli S, Spalinger J, Swiss IBD Cohort Study Group Abstract BACKGROUND: In ulcerative colitis (UC) 5-aminosalicylic acid (5-ASA) is recommended as primary therapy for mild to moderate disease. Topical 5-ASA has been proven especially effective. In Crohn’s disease (CD) the evidence for a beneficial role of 5-ASA is weak. We investigated the use of topical and systemic 5-ASA therapy in…

Read More

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 Jun 01;: Authors: D’Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG Abstract BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). AIM: To compare the efficacy and…

Read More

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians’ practice.

Related Articles Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians’ practice. World J Gastroenterol. 2017 Apr 28;23(16):2995-3002 Authors: Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN Abstract AIM: To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates (5ASA) with corticosteroids (CS) versus corticosteroids alone for patients with active ulcerative…

Read More

Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.

Related Articles Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. J Crohns Colitis. 2017 May 01;11(5):527-533 Authors: Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, On A, Levine A Abstract Background: Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing. In this induction of remission, investigator-blinded, randomised controlled-trial, we…

Read More

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. Inflamm Bowel Dis. 2017 Mar 31;: Authors: Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T, Yokoyama T, Okubo T, Hibi T Abstract BACKGROUND: The noninferiority of pH-dependent release mesalamine (Asacol) once daily (QD) to 3 times daily (TID) administration was investigated. METHODS: This was a phase 3, multicenter, randomized, double-blind, parallel-group, active-control study, with dynamic and stochastic allocation…

Read More

Mesalamine enemas for induction of remission in oral mesalamine refractory pediatric ulcerative colitis: a prospective cohort study.

Mesalamine enemas for induction of remission in oral mesalamine refractory pediatric ulcerative colitis: a prospective cohort study. J Crohns Colitis. 2017 Mar 23;: Authors: Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, Sarbagili Shabat C, Focht G, Shachmon E, Boaz M, On A, Turner D Abstract Background: Paediatric Ulcerative Colitis (UC) is more extensive than adult disease, and more often refractory to mesalamine. However, no prospective trials have evaluated mesalamine enemas for inducing remission…

Read More

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial. J Crohns Colitis. 2017 Mar 04;: Authors: Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP Abstract Background and Aims.: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted delivery throughout the colon, was examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesalamine therapy. Methods.: A randomized, double-blind, placebo-controlled, multicenter trial…

Read More
<< Go Back